Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.57 |
| ▸ | MAPT | P10636 | 3/20 | 0.53 |
| ▸ | TP53 | P04637 | 2/20 | 0.53 |
| ▸ | GLA | P06280 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | THRB | P10828 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2711768 | 0.93 | LMNA (0.57) | LMNAMAPTTP53GLAGAA | |
| SCHEMBL2860117 | 0.87 | SMN1; SMN2 (0.53) | LMNAMAPTTP53THRBPOLB | |
| SCHEMBL2711779 | 0.83 | TP53 (0.53) | LMNAMAPTTP53THRBPOLB | |
| SCHEMBL2710063 | 0.81 | LMNA (0.52) | LMNAMAPTTP53THRBPOLB | |
| SCHEMBL20135500 | 0.81 | SMN1; SMN2 (0.52) | LMNAPOLBGRIN2BSMN1; SMN2NPC1 | |
| SCHEMBL3107460 | 0.80 | GRIN2B (0.50) | LMNAMAPTTP53GRIN2BSMN1; SMN2 | |
| SCHEMBL8316392 | 0.79 | SMN1; SMN2 (0.61) | LMNAGRIN2BSMN1; SMN2NPC1RAB9A | |
| SCHEMBL10638044 | 0.79 | SMN1; SMN2 (0.48) | SMN1; SMN2NPC1RAB9APDE4BCYP2C19 | |
| SCHEMBL2709362 | 0.79 | NPC1 (0.54) | LMNAMAPTTP53THRBPOLB | |
| SCHEMBL2709553 | 0.79 | CETP (0.48) | LMNAMAPTTP53POLBGRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7790725-B2 | Thiazolidine derivatives and medicinal use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-09-07 | — | — | US | disclosed |
| US-20070259880-A1 | THIAZOLIDINE DERIVATIVES AND MEDICINAL USE THEREOF | MITSUBISHI PHARMA CORPORATION (JP) | 2007-11-08 | — | — | US | disclosed |
| US-20040259883-A1 | Thiazolidine derivative and medicinal use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2004-12-23 | — | — | US | disclosed |
| EP-1426366-A1 | THIAZOLIDINE DERIVATIVE AND MEDICINAL USE THEREOF | Mitsubishi Pharma Corporation (JP) | 2004-06-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259880-A1 | THIAZOLIDINE DERIVATIVES AND MEDICINAL USE THEREOF | DPP4, DPP7, DPP3 | LMNA 4632/4885MAPT 3150/4885TP53 3969/4885 |
| US-20040259883-A1 | Thiazolidine derivative and medicinal use thereof | DPP4, DPP7, DPP3 | LMNA 4727/4885MAPT 3522/4885TP53 4239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.